SanBio Company Limited
【Sambio】Reimbursement Listing and Future Developments of Akugo Brain Transplant Injection｜May 2026
Sambio officially secured reimbursement listing for Akugo🄬 Brain Transplant Injection on May 20, 2026, and is promoting clinical trials and global expansion. It obtained manufacturing and sales approval in July 2024 and plans to begin initial shipments from August 2026.
Key Figures
- Reimbursement amount: 72,716,528 yen
- Manufacturing and sales approval date: July 31, 2024
- Preparation for clinical trials: Unknown
AI要約
Performance Overview
Sambio officially secured reimbursement listing for Akugo🄬 Brain Transplant Injection on May 20, 2026, and obtained manufacturing and sales approval on July 31, 2024. It plans to advance clinical trials and gradually introduce the product to medical institutions. Initial shipments are scheduled from August 2026 to January 2027, with a focus on global expansion and broadened indications.
Future Outlook and Strategies
Sambio is progressing clinical trials of Akugo🄬 primarily through medical institutions, building a healthcare collaboration system that considers patient administration and rehabilitation. In the United States, preparations for phase 3 trials are underway, with plans to expand indications to include stroke and other conditions. The company is actively pursuing medium- to long-term growth opportunities.
Sambio Inc.
Company overview · Stock price · Financial data · All IR
